Joanne Wuensch
Stock Analyst at Citigroup
(4.29)
# 384
Out of 5,141 analysts
451
Total ratings
63.27%
Success rate
11.17%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Maintains: Neutral | $75 → $92 | $84.85 | +8.43% | 10 | Feb 20, 2026 | |
| BLCO Bausch + Lomb | Maintains: Buy | $20 → $21 | $17.94 | +17.06% | 7 | Feb 19, 2026 | |
| PODD Insulet | Maintains: Buy | $380 → $345 | $241.89 | +42.63% | 17 | Feb 19, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $94 → $98 | $98.75 | -0.76% | 24 | Feb 11, 2026 | |
| HAE Haemonetics | Maintains: Neutral | $88 → $75 | $61.19 | +22.57% | 11 | Feb 6, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $130 → $102 | $74.58 | +36.77% | 36 | Feb 5, 2026 | |
| ISRG Intuitive Surgical | Maintains: Neutral | $635 → $590 | $504.05 | +17.05% | 19 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Buy | $155 → $140 | $112.21 | +24.77% | 23 | Jan 23, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $232 → $250 | $242.49 | +3.10% | 17 | Jan 22, 2026 | |
| PEN Penumbra | Downgrades: Neutral | $350 → $374 | $339.36 | +10.21% | 27 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $455 → $420 | $380.23 | +10.46% | 15 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $9.1 | $5.40 | +68.52% | 14 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $113 → $125 | $120.27 | +3.93% | 23 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $88 | $84.23 | +4.48% | 8 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $75 | $76.00 | -1.32% | 8 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $96 → $101 | $79.78 | +26.60% | 22 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $22 | $24.57 | -10.46% | 21 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $77 | $73.08 | +5.36% | 17 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $88 | $84.07 | +4.67% | 22 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $11 | $12.21 | -9.91% | 16 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $21 | $21.58 | -2.69% | 22 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $205 → $242 | $150.96 | +60.31% | 22 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $112 | $96.86 | +15.63% | 22 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $4.15 | $1.51 | +175.75% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $185.39 | +34.85% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $82.63 | -16.50% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $259.12 | -50.99% | 6 | Dec 10, 2018 |
Integer Holdings
Feb 20, 2026
Maintains: Neutral
Price Target: $75 → $92
Current: $84.85
Upside: +8.43%
Bausch + Lomb
Feb 19, 2026
Maintains: Buy
Price Target: $20 → $21
Current: $17.94
Upside: +17.06%
Insulet
Feb 19, 2026
Maintains: Buy
Price Target: $380 → $345
Current: $241.89
Upside: +42.63%
Zimmer Biomet Holdings
Feb 11, 2026
Maintains: Neutral
Price Target: $94 → $98
Current: $98.75
Upside: -0.76%
Haemonetics
Feb 6, 2026
Maintains: Neutral
Price Target: $88 → $75
Current: $61.19
Upside: +22.57%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $130 → $102
Current: $74.58
Upside: +36.77%
Intuitive Surgical
Jan 23, 2026
Maintains: Neutral
Price Target: $635 → $590
Current: $504.05
Upside: +17.05%
Abbott Laboratories
Jan 23, 2026
Maintains: Buy
Price Target: $155 → $140
Current: $112.21
Upside: +24.77%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $232 → $250
Current: $242.49
Upside: +3.10%
Penumbra
Jan 16, 2026
Downgrades: Neutral
Price Target: $350 → $374
Current: $339.36
Upside: +10.21%
Dec 11, 2025
Maintains: Buy
Price Target: $455 → $420
Current: $380.23
Upside: +10.46%
Dec 11, 2025
Maintains: Neutral
Price Target: $5.5 → $9.1
Current: $5.40
Upside: +68.52%
Dec 11, 2025
Maintains: Buy
Price Target: $113 → $125
Current: $120.27
Upside: +3.93%
Dec 11, 2025
Maintains: Neutral
Price Target: $83 → $88
Current: $84.23
Upside: +4.48%
Dec 11, 2025
Maintains: Neutral
Price Target: $62 → $75
Current: $76.00
Upside: -1.32%
Dec 11, 2025
Maintains: Buy
Price Target: $96 → $101
Current: $79.78
Upside: +26.60%
Dec 11, 2025
Maintains: Neutral
Price Target: $16 → $22
Current: $24.57
Upside: -10.46%
Dec 11, 2025
Maintains: Buy
Price Target: $75 → $77
Current: $73.08
Upside: +5.36%
Dec 8, 2025
Maintains: Neutral
Price Target: $72 → $88
Current: $84.07
Upside: +4.67%
Oct 31, 2025
Maintains: Sell
Price Target: $12 → $11
Current: $12.21
Upside: -9.91%
Oct 31, 2025
Maintains: Neutral
Price Target: $26 → $21
Current: $21.58
Upside: -2.69%
Oct 31, 2025
Maintains: Buy
Price Target: $205 → $242
Current: $150.96
Upside: +60.31%
Oct 7, 2025
Maintains: Buy
Price Target: $101 → $112
Current: $96.86
Upside: +15.63%
May 22, 2025
Maintains: Neutral
Price Target: $6.5 → $4.15
Current: $1.51
Upside: +175.75%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $185.39
Upside: +34.85%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $82.63
Upside: -16.50%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $259.12
Upside: -50.99%